Introduction: Several lines of evidence indicate that increased inflammation is associated with Post-Traumatic Stress Disorder (PTSD). We have previously reported that peripheral inflammatory markers are significantly higher in combat-exposed veterans with than without PTSD. This study was designed to replicate these findings in a new study cohort using the same population and recruitment strategies. Methods: Sixty-one male war veterans (31 PTSD and 30 control subjects) were included in this replication study. Levels of Interleukin-6, Tumor Necrosis Factor-alpha, Gamma interferon, and high-sensitivity C-reactive protein were quantified in blood samples. A standardized ''total pro-inflammatory score" was calculated to limit the number of statistical comparisons. The Clinician Administered PTSD Scale (CAPS) rating scale was used to assess PTSD symptom severity. Results: PTSD subjects had significantly higher total pro-inflammatory scores compared to non-PTSD subjects in unadjusted analysis (Cohen's d = 0.75, p = 0.005) as well as after adjusting for potentially confounding effects of age, BMI, smoking, and potentially interfering medications and somatic co-morbidities (p = 0.023). There were no significant correlations between inflammatory markers and severity of symptoms within the PTSD group. Conclusions: We replicated, in a new sample, our previous finding of increased inflammatory markers in combat-exposed PTSD subjects compared to combat-exposed non-PTSD controls. These findings strongly add to the growing literature suggesting that immune activation may be an important aspect of PTSD pathophysiology, although not directly correlated with current PTSD symptom levels in the PTSD group.
Introduction
Post Traumatic Stress Disorder (PTSD) is a debilitating condition that places a high burden on patients, their families, and society at large. War veterans are at a particularly high risk of developing PTSD. Between 12 and 18% of soldiers returning from the conflicts in Iraq and Afghanistan suffer from PTSD (Hoge et al., 2004) , and the prevalence rates are even higher in Veterans Affairs healthcare settings (Seal et al., 2009) . Biomarkers for PTSD are needed in order to identify subjects at high risk, determine a more accurate diagnosis, track disease progression, better understand the underlying pathophysiology and develop novel treatment options. Several lines of evidence suggest that PTSD is associated with immune activation (Altemus et al., 2003; Passos et al., 2015) . Many (Baker et al., 2001; Hoge et al., 2009; Maes et al., 1999; Spitzer et al., http://dx.doi.org/10.1016/j.bbi.2016.09.012 0889-1591/Ó 2016 Elsevier Inc. All rights reserved.
